Clinical Trials Browser

Neoplasm, Residual × Rituximab × 1 year × Clear all

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT05735717 2025-07-24

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2 Active not recruiting

69 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Phase 2 Active not recruiting

37 enrolled 9 charts

Lymphoid

Neoplasm, Residual, Lymphoma, Mantle-Cell

Clinical Trials

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL